13/09/2026 First-time outcomes from the failed Ph3 EVOKE-03 study of sacituzumab govitecan-hziy+ pembro in Tx naive PD-L1 ≥50% NSCLC pts presented at WCLC'26 First-time outcomes from the failed Ph3 EVOKE-03 study of sacituzumab govitecan-hziy+ pembro in Tx naive PD-L1 ≥50% NSCLC pts presented at WCLC'26 (abstract #PL02.06; Ref) The first reported efficacy and safety outcomes from the Ph3 KEYNOTE-D46/EVOKE-03 trial of Gilead's sacituzumab govitecan-hziy (SG; TROP2 ADC) + Merck

🤝 Bristol Myers Squibb is set to acquire 2seventy bio in an all-cash transaction valued at approximately $286 million. After accounting for 2seventy bio’s cash reserves, the net acquisition cost for BMS stands at around $102 million. The deal is expected to close in H2'25. 👉 This acquisition gives BMS full control of Abecma (idecabtagene vicleucel), a BCMA-targeted CAR-T cell therapy indicated for the treatment of adult patients with R/R multiple myeloma after two or more p

Bladder cancer is the most common malignancy of the urinary tract. As of 2022, Bladder Cancer had an incidence of 614,298 patients worldwide, and 220,596 patients succumbed to the disease. While the therapeutic approach to it remained largely unchanged for many years, recent clinical progress has paved the way towards a novel era of diagnosis and management of the disease, with several special designations and two very recent approvals by the US FDA. In December 2023, the FD

PD-(L)1 axis inhibits CAR-T cell activation, proliferation, survival, and functionality. Thus, CAR-T mediated direct targeting of the PD-(L)1 immunosuppressive axis or modulation of the axis along with CAR-T therapy holds a huge promise to unleash the full potential of CAR-Ts. Multiple strategies are under investigation to target PD-(L)1 immunosuppressive axis to increase CAR-T therapy efficacy. We have grouped the strategies under the following three broad categories, Combin